Phase II study of topotecan in patients with extensive-stage small- cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial

Journal of Clinical Oncology

Volumn 14, Issue 8, 1996, Pages 2345-2352

  Schiller, J H ^a   Kim, K ^a   Hutson, P ^a   DeVore, R ^a   Glick, J ^a   Stewart, J ^a   Johnson, D ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 0029790139     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.8.2345     Document Type: Article

References (31)

1. Comis RL: Chemotherapy of small cell lung cancer. Principles Practice Oncol Updates 1:1-18, 1987
2. Ihde D: Chemotherapy of lung cancer. N Engl J Med 327:1434-1441, 1992
3. Moore T, Korn E: Phase II trial design considerations for small-ceil lung cancer. J Natl Cancer Inst 84:150-154, 1992
4. Ettinger D: Evaluation of new drugs in untreated patients with small-cell lung cancer: Its time has come. J Clin Oncol 8:374-377, 1990
5. Liu L: DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 58:351-375, 1989
6. Chabner B: Camptothecins. J Clin Oncol 10:3-4, 1992
7. Rowinsky E, Grochow L, Hendricks C, et al: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
8. Ettinger D, Finkelstein D, Abeloff M, et al: Justification for evaluating new anti-cancer drugs in selected untreated patients with a chemotherapy-sensitive advanced cancer: An ECOG randomized study. Proc Am Soc Clin Oncol 9:224, 1990 (abstr)
9. Kruskal WH, Wallis WA: Use of ranks in one-criterion variance analysis. J Am Stat Assoc 47:583-612, 1952
10. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
11. Cleveland WS: Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 74:829-836, 1979
12. Cox DR, Snell EJ: Analysis of Binary Data (ed 2). London, United Kingdom, Chapman & Hall, 1989
13. D'Argenio DZ, Schumitzky A: ADAPT II User's Guide. University of Southern California, Los Angeles, CA, Biomedical Simulations Resource, 1992
14. Grochow LB, Rowinsky EK, Johnson R, et al: Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 20:706-713, 1992
15. Conti J, Kemeny N, Saltz L, et al: Irinotecan (CPT-11) is an active agent in untreated patients (pts) with metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 13:195, 1994 (abstr)
16. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20, 1992
17. Masuda N, Fukuoka M, Kudoh S, et al: Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 12:90-96, 1994
18. Rougier P, Culine S, Bagat R, et al: Multicentric phase II study of first line CPT-11 (Irinotecan) in advanced colorectal cancer (CRC): Preliminary results. Proc Am Soc Clin Oncol 13:200, 1994 (abstr)
19. Bugat R, Sue E, Rougier P, et al: CPT-11 (Irinotecan) as second line therapy in advanced colorectal cancer (CRC): Preliminary results of a multicentric phase II study. Proc Am Soc Clin Oncol 13:200, 1994 (abstr)
20. Saltz L, Sirott M, Young C, et al: Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony stimulation factor. J Natl Cancer Inst 85:1499-1507, 1993
21. Lynch T, Kalish L, Strauss G, et al: Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 12:347-352, 1994
22. Wanders J, Ardizzoni A, Hansen HH, et al: Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC). Proc Am Assoc Cancer Res 36:237, 1995 (abstr)
23. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
24. Fujiwara Y, Yamakido M, Fukuoka M, et al: Phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in patients with small cell lung cancer. Proc Am Soc Clin Oncol 13:335, 1994 (abstr)
25. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al: The current status of camptothecin analogs as antitumor agents. J Natl Cancer Inst 85:271-291, 1993
26. D'Arpa P, Beardmore C, Liu LF: Involvement of nucleic acid synthesis in cell-killing mechanisms of topoisomerase poisons. Cancer Res 50:6919-6924, 1990
27. Bertrand R, O'Connor PM, Kerrigan D, et al: Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon-carcinoma HT-29 cells. Eur J Cancer 28A:743-748, 1992
28. Anzi H, Frost P, Abbruzzese JL: Synergistic cytotoxicity with combined inhibition of topoisomerase I and II. Proc Am Soc Clin Oncol 33:431, 1992 (abstr)
29. Kirn R, Hirabayashi N, Nishama M, et al: Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 50:760-766, 1992
30. Kaufmann S: Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51:1129-1136, 1991
31. Klasa R, Murray N, Coldman A: Dose intensity meta-analysis of chemotherapy regimens in small cell carcinoma of the lung. J Clin Oncol 9:499-508, 1991